Loading...
Loading...
PPBT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 49.0K |
| Gross Profit | -49.0K |
| Operating Expense | 3,458.0K |
| Operating I/L | -3,458.0K |
| Other Income/Expense | 1,043.0K |
| Interest Income | 121.0K |
| Pretax | -2,415.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -2,405.0K |
Purple Biotech Ltd. is a clinical-stage company focused on developing therapies to address tumor immune evasion and drug resistance in cancer patients. The company's oncology pipeline includes CM24, a monoclonal antibody in Phase 1b/2 clinical trials for non-small cell lung cancer and pancreatic cancer, and NT219, a small molecule in Phase 1/2 clinical trials for recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. Purple Biotech aims to generate revenue through the development and commercialization of these innovative therapies to improve outcomes for cancer patients.
